Press Releases

08/27/2014

Cempra to present at three investor conferences
CHAPEL HILL, N.C., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at three upcoming investor conferences.

 
08/12/2014

Cempra Initiates Phase 3 Clinical Trial in Patients with Uncomplicated Gonorrhea Infection
CHAPEL HILL, N.C., Aug. 12, 2014 -- Cempra, Inc., (Nasdaq: CEMP) today announced the initiation of a Phase 3 clinical trial, called Solitaire-U, of a single 1000 mg dose of oral solithromycin in patients with uncomplicated Neisseria gonorrhea and chlamydia infections.

07/29/2014

Cempra, Inc. Reports Second Quarter 2014 Financial and Operating Results
CHAPEL HILL, N.C., July 29, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the second quarter and six months ended June 30, 2014.

07/22/2014

Cempra, Inc. to Report Second Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on July 29, 2014
CHAPEL HILL, N.C., July 22, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that it will report second quarter 2014 financial results and provide a business update after the close of U.S. financial markets on July 29, 2014.

06/17/2014

Cempra, Inc. to Present at JMP Securities Healthcare Conference
CHAPEL HILL, N.C., June 17, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at the JMP Securities Healthcare Conference at 10:30 a.m. EDT, Tuesday, June 24, at The Westin New York Grand Central in New York City. 

05/09/2014

Cempra to Present Data on Solithromycin at ECCMID Highlighting Potential New Indications, Safety and Activity Spectrum
Chapel Hill, NC, May 9, 2014 – Cempra, Inc. (Nasdaq: CEMP) today announced that it will present data at the  European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain, that continue to enhance the profile of solithromycin in regards to potential new indications, safety and spectrum of activity particularly against contemporary strains.

05/08/2014

Cempra, Inc. to Present at Three Investor Conferences
CHAPEL HILL, N.C., May 8, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at three upcoming investor conferences.

05/06/2014

Cempra Presents Late-Breaker on Solithromycin’s Anti NASH Effects in an Animal Model at DDW 2014
CHAPEL HILL, N.C., May 6, 2014 -- Cempra, Inc., (Nasdaq: CEMP) today announced a late-breaker presentation demonstrating that solithromycin significantly reduced ballooning degeneration and inflammation which are histological signs of non-alcoholic steatohepatitis (NASH) in an animal model at Digestive Disease Week (DDW) in Chicago.

04/29/2014

Cempra, Inc. Reports First Quarter 2014 Financial and Operating Results 
CHAPEL HILL, N.C. – April 29, 2013 – Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the first quarter ended March 31, 2014. 

04/22/2014

Cempra, Inc. to Report First Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on April 29, 2014
CHAPEL HILL, N.C., April 22, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that it will report first quarter 2014 financial results and provide a business update after the close of U.S. financial markets on April 29, 2014. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra will host a conference call and webcast at 4:30 p.m. EDT, April 29, 2014.

04/01/2014

Cempra's Solithromycin Demonstrates Therapeutic Potential Beyond Anti-Bacterial Activity
CHAPEL HILL, N.C., April 3, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced the presentation of a late-breaking abstract entitled "Anti-NASH Effects of Solithromycin in NASH-HCC Mouse Model," at 9:15 a.m. EDT, May 6, at Digestive Disease Week (DDW®) 2014 in Room S105A at McCormick Place in Chicago.

03/27/2014

Cempra to Present Late-Breaker on Solithromycin Reducing Inflammation in an Animal Model for Cancer Chemotherapy-Induced Lung Injury
CHAPEL HILL, N.C., March 27, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc., (Nasdaq:CEMP) today announced a late-breaker presentation demonstrating that solithromycin reduced inflammation in an animal model for inflammatory lung disease at the American Thoracic Society (ATS) 2014 International Conference in San Diego.

03/20/2014

Cempra, Inc. to Present at The 21st Annual Future Leaders in the Biotech Industry Conference and Needham & Co. 12th Annual Healthcare Conference
CHAPEL HILL, N.C., March 20, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at The 21st Annual Future Leaders in the Biotech Industry Conference at 11:30 a.m. EDT, Friday, March 28, at the Millennium Broadway Hotel & Conference Center in New York City and at the Needham & Co. 12th Annual Healthcare Conference at 12:50 p.m. EDT, Wednesday, April 9, at The Westin New York Grand Central in New York City.

03/06/2014

Cempra, Inc. to Present at Barclays Capital 2014 Global Healthcare Conference and 26th Annual ROTH Conference
CHAPEL HILL, N.C., March 6, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at the Barclays Capital 2014 Global Healthcare Conference at 3:45 p.m. EST, Wednesday, March 12, at the Loews Miami Hotel in Miami Beach, Fla. and at the 26th Annual ROTH Conference at 3:30 p.m. PST, Monday, March 10, at The Ritz Carlton in Laguna Niguel, Calif. 

 
02/27/2014

Cempra, Inc. Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
CHAPEL HILL, N.C., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the fourth quarter and full year ended Dec. 31, 2013.

 
02/20/2014

Cempra, Inc. to Report Fourth Quarter and Full Year 2013 Financial and Operating Results, and Host Conference Call and Webcast on Feb. 27, 2014
CHAPEL HILL, N.C., Feb. 20, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that it will report fourth quarter and full year 2013 financial results and provide a business update after the close of U.S. financial markets on Feb. 27, 2014.

02/20/2014

Cempra Initiates Solithromycin Pediatric Program
CHAPEL HILL, N.C., Feb. 20, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced the dosing of the first patient in its Phase 1 study of solithromycin capsules in children. The clinical trial is funded through Cempra's contract with the Biomedical Advanced Research and Development Authority (BARDA; http://www.phe.gov/about/barda/Pages/default.aspx).

02/19/2014

Cempra, Inc. to Present at RBC Capital Markets 2014 Global Healthcare Conference and Cowen 34th Annual Health Care Conference
CHAPEL HILL, N.C., Feb. 19, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at the RBC Capital Markets 2014 Global Healthcare Conference at 1:35 p.m. EST, Tuesday, Feb. 25, at The New York Palace Hotel in New York City, and at the Cowen 34th Annual Health Care Conference at 1:30 p.m. EST, Monday, March 3, at The Boston Marriott Copley Place in Boston.

02/11/2014

Cempra's Solithromycin Demonstrates No QT Effects in Thorough QT Study
CHAPEL HILL, N.C., Feb. 11, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that solithromycin demonstrated no QT effects at single intravenous (IV) doses of 800 mg in a Thorough QT (TQT) study.

02/04/2014

Cempra, Inc. to Present at BIO CEO & Investor Conference and 2014 Leerink Global Healthcare Conference
CHAPEL HILL, N.C., Feb. 4, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at the BIO CEO & Investor Conference at 1 p.m. EST, Tuesday, Feb. 11, and at the 2014 Leerink Global Healthcare Conference at 2:40 p.m. EST, Wednesday, Feb. 12.

01/07/2014

Cempra, Inc. Names David Moore as Chief Commercial Officer to Manage Commercial Development and Launch of Solithromycin and Taksta(TM)
CHAPEL HILL, N.C., Jan. 7, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced the appointment of David Moore as executive vice president and chief commercial officer (CCO) to manage the commercial development and launch of solithromycin and Taksta(TM).

12/16/2013

Cempra, Inc., Provides Update on Clinical Development of Solithromycin and Taksta(TM)
CHAPEL HILL, N.C., Dec. 16, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), today provided an update on the clinical development of solithromycin and Taksta(TM). Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will host a conference call and webcast at 4:30 p.m. EST, today, to discuss the current status of the company's clinical programs.

12/16/2013

Cempra, Inc. to Host Solithromycin and TAKSTA Clinical Update Conference Call and Webcast
CHAPEL HILL, N.C., Dec. 16, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that it will provide an update on the clinical development of solithromycin (CEM-101) and TAKSTA™ (CEM-102). Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra will host a conference call and webcast at 4:30 p.m. EST, today, Dec. 16, 2013. 

12/02/2013

Cempra, Inc. to Present at Piper Jaffray 25th Annual Healthcare Conference and Oppenheimer 24th Annual Healthcare Conference
CHAPEL HILL, N.C., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at the Piper Jaffray 25th Annual Healthcare Conference at 2:30 p.m. EST, Wednesday, Dec. 4, at The New York Palace Hotel, and at the Oppenheimer 24th Annual Healthcare Conference at 3:55 p.m. EST, Wednesday, Dec. 11, at The Crowne Plaza Hotel in New York City. 

11/18/2013

Preclinical Study Suggests That Solithromycin May Provide an Effective Antimicrobial Approach for Prevention and Treatment of Intrauterine Infections in Pregnancy
CHAPEL HILL, N.C., Nov. 18, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc., (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced results of an in vivo preclinical study suggesting that solithromycin (CEM-101) may provide an effective antimicrobial approach for the prevention and treatment of intrauterine infections during pregnancy.

11/12/2013

Cempra, Inc. to Present at Jefferies 2013 London Healthcare Conference and 2013 Therapeutic Area Partnerships (TAP) Conference
CHAPEL HILL, N.C., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at the Jefferies 2013 London Healthcare Conference at 1 p.m. GMT, Wednesday, Nov. 20, at The Waldorf Hilton in London. 

10/29/2013

Cempra, Inc. Receives U.S. Orphan Drug Designation for Taksta (TM) for Treatment of Prosthetic Join Infections 
CHAPEL HILL, N.C., Oct. 29, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP),  a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its drug candidate Taksta™ (CEM-102) for the treatment of prosthetic joint infections (PJI).

10/29/2013

Cempra, Inc. Reports  Third Quarter 2013 Financial and Operating Results 2013
CHAPEL HILL, N.C., Oct. 29, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the third quarter and nine months ended September 30, 2013

10/22/2013

Cempra, Inc. to Report  Third Quarter 2013 Financial and Operating Results, and Host Conference Call and Webcast on Oct. 29, 2013
CHAPEL HILL, N.C., Oct. 22, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that it will report third quarter 2013 financial results and provide a business update after the close of U.S. financial markets on Oct. 29, 2013.

10/21/2013 Cempra, Inc. to Present at NewsMakers in the Biotech Industry Conference 
CHAPEL HILL, N.C., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP),today announced that Carl Foster, executive vice president, business development, for Cempra, will present at the Second Annual Generating Evidence for Reimbursement Decisions: Therapeutics Conference at 4:15 p.m. EDTMonday, Oct. 21, at the Hyatt Regency in Bethesda, Md. 
09/19/2013 Cempra, Inc. to Present at NewsMakers in the Biotech Industry Conference 
CHAPEL HILL, N.C., Sept. 19, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the NewsMakers in the Biotech Industry conference at 1:30 p.m. EDTFriday, Sept. 27, at the Millennium Broadway Hotel & Conference Center in New York.
09/10/2013 Cempra to Present Data at ICAAC on Solithromycin's (CEM-101) Activity Against a Broad Range of Pathogens Including Four Proposed or Designated by the Food and Drug Administration as Qualified Infectious Disease Pathogens (QIDP) Under the Generating Antibiotic Incentives Now (GAIN) Act 
CHAPEL HILL, N.C., Sept. 10, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP),  a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it will present data at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Colorado, showing the marked activity of solithromycin against a broad range of pathogens including four proposed or designated by the Food and Drug Administration (FDA) as qualified infectious disease pathogens (QIDP) under the Generating Antibiotic Incentives Now (GAIN) Act. 
09/06/2013 Cempra's Solithromycin (CEM-101) Receives Qualified Infectious Disease Product Designation From the U.S. Food and Drug Administration
CHAPEL HILL, N.C., Sept. 6, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has designated oral Solithromycin (CEM-101), as a Qualified Infectious Disease Product (QIDP) for the indication of community-acquired bacterial pneumonia. 
09/05/2013 Cempra's Solithromycin Demonstrates Safety and Tolerability in Patients with Chronic Liver Disease 
CHAPEL HILL, N.C., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP),  clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that solithromycin demonstrated safety and tolerability in patients with mild to severe chronic liver disease.
09/03/2013 Cempra, Inc. to Present at Baird's 2013 Health Care Conference and Stifel Healthcare Conference 2013 
CHAPEL HILL, N.C.Sept. 3, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that Mark Hahn, executive vice president and chief financial officer of Cempra, will present at Baird's 2013 Health Care Conference at 1:45 p.m. EDTSept. 11, at The New York Palace Hotel in New York, and at the Stifel Healthcare Conference 2013 at 8:35 a.m. EDTSept. 12, at the Four Seasons Hotel in Boston.
07/30/2013 Cempra, Inc. Reports Second Quarter 2013 Financial and Operating Results 
CHAPEL HILL, N.C.July 30, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the second quarter and six months ended June 30, 2013. The company will host a conference call and webcast at 4:30 p.m. EDT, today. 
07/23/2013 Cempra, Inc. to Report Second Quarter 2013 FInancial and Operating Results, and Host Conference Call and Webcast on July 30, 2013
CHAPEL HILL, N.C.July 23, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq: CEMP), today announced that it will report second quarter 2013 financial results and provide a business update after the close of U.S. financial markets on July 30, 2013. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will host a conference call and webcast at 4:30 p.m. EDT, July 30, 2013.
06/19/2013 Cempra, Inc. Announces Partial Exercise of Over-Allotment Option and Completion of the Public Offering of Common Stock
CHAPEL HILL, N.C.June 19, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it has completed its previously announced underwritten public offering of 7,250,000 shares of common stock, plus an additional 1,023,938 shares issued pursuant to the partial exercise by the underwriters of their over-allotment option, at a public offering price of $7.00 per share.

 

06/14/2013

Cempra, Inc. 

Prices Public Offering of Common Stock 

 
CHAPEL HILL, N.C.June 14, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it has priced an underwritten public offering of 7,250,000 shares of its common stock at a price of $7.00 per share.
06/13/2013 Cempra, Inc. Provides Guidance on the Clinical Program Required for Regulatory Approval for Solithromycin for Community-Acquired Bacterial Pneumonia (CABP) 
CHAPEL HILL, N.C.June 13, 2013 /PRNewswire/ -- Cempra, Inc.(Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today described the steps expected for regulatory approval for solithromycin for community-acquired bacterial pneumonia (CABP). 
06/13/2013 Cempra, Inc. Announces Proposed Public Offering of Common Stock
CHAPEL HILL, N.C.June 13, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. 
05/30/2013 Cempra, Inc. to Announces Notification of Patent Allowance for U.S. Patent Application on Taksta Loading Dose Formulation
CHAPEL HILL, N.C., May 30, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP),a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,450,300 on May 28, 2013 with claims directed to the company’s novel loading dose regimen for Taksta™. 
05/29/2013 Cempra, Inc. to Present at Jefferies 2013 Global Healthcare Conference
CHAPEL HILL, N.C., May 29, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the Jefferies 2013 Global Healthcare Conference at 1 p.m. EDT, Wednesday, June 5, at the Grand Hyatt in New York.
05/28/2013 Cempra, Inc. Awarded $58 Million Contract to Develop Antibiotic for Pediatric Use and Biodefense by Biomedical Advanced Research and Development Authority (BARDA)
CHAPEL HILL, N.C., May 28, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Cempra with a five year contract valued up to $58 million for the development of solithromycin to treat infections in pediatric populations and for the treatment of infections by bioterror threat pathogens.
05/20/2013 Cempra, Inc. Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP)
CHAPEL HILL, N.C., May 20, 2013 /PRNewswire/ -- Cempra, Inc., (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it presented data at the American Thoracic Society International Conference (ATS 2013) in Philadelphia demonstrating the antibacterial and enhanced immunomodulatory activity of solithromycin versus levofloxacin in Cempra’s prior Phase 2 clinical trial in outpatients with community acquired bacterial pneumonia (CABP).
05/13/2013 Cempra, Inc. Signs Exclusive License and Development Agreement for Solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation in Japan
CHAPEL HILL, N.C., May 13, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical needs in the treatment of bacterial infections, today announced the signing of an exclusive license and development agreement for solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation in Japan. The company will host a conference call and webcast at 4:30 p.m. EDT, today, to discuss the agreement.
04/26/2013 Cempra, Inc. to Present Data on Solithromycin’s (CEM-101) Potential Against Urogenital Infections and Multidrug-Resistant Pathogens at ECCMID
CHAPEL HILL, N.C., April 26, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it will present data at the  European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Berlin, demonstrating solithromycin’s potential to treat urogenital infections and combat challenging pathogens such as enterococci and Legionella pneumophila.
04/25/2013 Cempra, Inc. Reports First Quarter 2013 Financial and Operating Results
CHAPEL HILL, N.C., April 25, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the first quarter ended March 31, 2013.
04/24/2013 Cempra, Inc. to Present at 12th Annual Needham Healthcare Conference
CHAPEL HILL, N.C., April 24, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the 12th Annual Needham Healthcare Conference at 1:40 p.m. EDT, Wednesday, May 1, at the Westin New York Grand Central Hotel in New York.
04/18/2013 Cempra, Inc. to Report First Quarter 2013 Financial and Operating Results, and Host Conference Call and Webcast on April 25, 2013
CHAPEL HILL, N.C., April 18, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that it will report first quarter 2013 financial results and provide a business update after the close of U.S. financial markets on April 25, 2013. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra will host a conference call and webcast at 4:30 p.m. EDT, April 25, 2013.
02/28/2013 Cempra, Inc. Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
CHAPEL HILL, N.C., Feb. 28, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the fourth quarter and full year ended Dec. 31, 2012.
02/26/2013 Cempra, Inc. to Present at Cowen and Company 33rd Annual Helath Care Conference
CHAPEL HILL, N.C., Feb. 26, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the Cowen and Company 33rd Annual Health Care Conference at 2:10 p.m. EST, Monday, March 4, at the Boston Marriott Copley Place in Boston.
02/21/2013 Cempra, Inc. to Report Fourth Quarter and Full Year 2012 Financial and Operating Results, and Host Conference Call and Webcast on February 28, 2013
CHAPEL HILL, N.C., Feb. 21, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that it will report fourth quarter and full year 2012 financial results and provide a business update after the close of U.S. financial markets on February 28, 2013. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra will host a conference call and webcast at 4:30 p.m. EST, February 28, 2013.
02/12/2013 Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes Studies on Cempra's Solithromycin (CEM-101) in a Cystic Fibrosis Anti-inflammatory Model
CHAPEL HILL, N.C., Feb. 12, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the National Institute of Allergy and Infectious Diseases (NIAID) awarded a grant to Richard C. Boucher, M.D., Kenan Professor of Medicine and director of the Cystic Fibrosis and Pulmonary Research and Treatment Center at the University of North Carolina School of Medicine, to investigate the anti-inflammatory activity of solithromycin and its effect on mucin secretion in models for cystic fibrosis (CF).
02/5/2013 Cempra, Inc. to Present at BIO CEO & Investor Conference and Leerink Swann Global Healthcare Conference
CHAPEL HILL, N.C., Feb. 5, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at the BIO CEO & Investor Conference at 9:30 a.m. EST, Feb. 12, at the Waldorf Astoria in New York, and at the Leerink Swann Global Healthcare Conference at 2 p.m. EST, Feb. 13, at the Waldorf Astoria in New York.
12/19/2012 Cempra, Inc. Announces Initiation of Oral Solithromycin Global Phase 3 Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia
CHAPEL HILL, N.C., Dec. 19, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the initiation of its global Phase 3 clinical trial of orally-administered solithromycin, the company's fluoroketolide antibiotic candidate, in patients with community-acquired bacterial pneumonia (CABP).
12/14/2012 Cempra, Inc. Announces Initiation of CEM-102 Phase 2 Clinical Trial in Patients with Prosthetic Joint Infections
CHAPEL HILL, N.C., Dec. 14, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the initiation of its Phase 2 clinical trial of CEM-102 in patients with prosthetic joint infections (PJIs). CEM-102 is the company's loading dose formulation of fusidic acid, an orally-active anti-staphylococcal agent with a long history of safety and efficacy outside of the U.S.
12/5/2012 Cempra, Inc. to Present at Oppenheimer 23rd Annual Healthcare Conference
CHAPEL HILL, N.C., Dec. 5, 2012 - Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the Oppenheimer 23rd Annual Healthcare Conference at 11:10 a.m. EST, Wednesday, Dec. 12, at the Waldorf=Astoria in New York City. Dr. Fernandes will provide an update of the company's two leading antibiotic clinical programs, solithromycin (CEM-101) for community-acquired bacterial pneumonia and its fusidic acid (CEM-102) for the chronic, oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.
11/9/2012 Cempra, Inc. to Present at the Jefferies 2012 Global Healthcare Conference in London
CHAPEL HILL, N.C., Nov. 9, 2012 - Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the Jefferies 2012 Global Healthcare Conference in London at 4:20 p.m. GMT, Thursday, Nov. 15, 2012, at the Waldorf Hilton in London. Dr. Fernandes will provide an update of the company's two leading antibiotic clinical programs, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA™ for the chronic, oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.
11/8/2012 Cempra, Inc. Reports Third Quarter 2012 Financial and Operating Results
CHAPEL HILL, N.C., Nov. 8, 2012 - Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the third quarter ended Sept. 30, 2012. The company will host a conference call and webcast at 4:30 p.m. EST, today.
11/1/2012 Cempra, Inc. to Report Third Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on November 8, 2012
CHAPEL HILL, N.C., Nov. 1, 2012 - Cempra, Inc. (Nasdaq: CEMP) today announced that it will report third quarter 2012 financial results and provide a business update after the close of U.S. financial markets on November 8, 2012. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra will host a conference call and webcast at 4:30 p.m. EST, November 8, 2012.
10/18/2012 Cempra Announces Pricing of $25 Million Private Placement
CHAPEL HILL, N.C., Oct. 18, 2012 - Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it has entered into a securities purchase agreement with a select group of new and existing institutional and accredited investors in connection with a private placement financing. Upon closing of the financing, Cempra will receive gross proceeds of approximately $25 million resulting from the sale of 3,864,461 shares of common stock at the purchase price of $6.50 per share. Jefferies & Company, Inc., Cowen and Company and Stifel Nicolaus Weisel served as placement agents for the financing.
10/17/2012 Cempra, Inc. Continues to Differentiate Solithromycin's Potency and Activity Compared to other Macrolides in Presentations at IDWeek 2012™
SAN DIEGO, Oct. 17, 2012 - Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that data show continued differentiation of the company's fourth-generation macrolide/fluoroketolide, solithromycin, from currently available macrolides. The data will be presented at the IDWeek 2012™ conference on Oct. 17- 21 in San Diego.
10/8/2012 Cempra, Inc. Announces Results of Intravenous Solithromycin Phase 1 Study
CHAPEL HILL, N.C., Oct. 8, 2012 - Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced results of its Phase 1 study of intravenous (IV) solithromycin in healthy subjects. The study demonstrated that IV solithromycin was well tolerated, showed a favorable pharmacokinetic profile (PK) and achieved relevant plasma concentrations.
10/4/2012 Cempra, Inc. Announces Positive Top-Line Results from Solithromycin Phase 2 Clinical Trial in Patients with Uncomplicated Urogenital Gonorrhea
CHAPEL HILL, N.C., Oct. 4, 2012 - Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced positive top-line data showing that solithromycin cleared infections in patients with uncomplicated urogenital gonorrhea. Patients with proven gonococcal infections were treated with a single oral dose of solithromycin.
9/7/2012 Cempra Inc : Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of Solithromycin at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
CHAPEL HILL, N.C., Sept. 7, 2012 - Cempra Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that data will be presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, Sept. 9 to 12.
8/29/2012 Cempra, Inc., to Present at 2012 Stifel Nicolaus Healthcare Conference and NewsMakers in the Biotech Industry Conference
CHAPEL HILL, N.C., Aug. 29, 2012 - Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at the 2012 Stifel Nicolaus Healthcare Conference at 10:20 a.m. EDT, Sept. 5, at the Four Seasons Hotel in Boston, and at the NewsMakers in the Biotech Industry conference at 9:30 a.m. EDT, Sept. 7, at the Millennium Broadway Hotel & Conference Center in New York.
8/9/2012 Curetis AG and Cempra, Inc. Collaborate on the Detection of Community-Acquired Bacterial Pneumonia
-Cempra to use Curetis' Unyvero™ solution in its Phase III trial of its antibiotic Solithromycin (CEM-101)-
Holzgerlingen, Germany, and Chapel Hill, N.C., USA August 9, 2012 - Curetis AG and Cempra Inc. (NASDAQ:CEMP) today announced a research and development collaboration to incorporate Curetis' Unyvero pneumonia molecular diagnostic system into Cempra's upcoming global Phase 3 trial of the oral formulation of solithromycin, in patients with community-acquired bacterial pneumonia (CABP).
8/8/2012 Cempra, Inc. Reports Second Quarter 2012 Financial and Operating Results
- Company to Host Conference Call and Webcast at 4:30 p.m. EDT, Today, Aug. 8, 2012 -
CHAPEL HILL, N.C., Aug. 8, 2012 -  Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the second quarter ended June 30, 2012. The company will host a conference call and webcast at 4:30 p.m. EDT, today.
8/6/2012 Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
CHAPEL HILL, N.C., Aug. 6, 2012 - Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the NIAID workshop Bridging the Gap — Overcoming  Bottlenecks in the Development of Therapeutics for Infectious Diseases on August 9 to 10 in Rockville, MD.
8/1/2012 Cempra, Inc. to Report Second Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on August 8, 2012
CHAPEL HILL, N.C., Aug. 1, 2012 - Cempra, Inc. (Nasdaq: CEMP) today announced that it will report second quarter 2012 financial results and provide a business update after the close of U.S. financial markets on August 8, 2012. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra will host a conference call and webcast at 4:30 p.m. EDT, August 8, 2012.
7/6/2012 Cempra, Inc. to Present at the Global Technology Community 9th Anti-Infectives Partnering and Deal-Making Conference
CHAPEL HILL, N.C., July 6, 2012 - Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the Global Technology Community 9th Anti-Infectives Partnering and Deal-Making Conference on July 9 to 10 at the San Francisco Airport Marriott Waterfront Hotel in San Francisco.
6/12/2012 Cempra Inc. Doses First Patients in Solithromycin (CEM-101) Phase 2 Trial in Uncomplicated Urogenital Gonococcal Infections
CHAPEL HILL, N.C., June 12, 2012 - Cempra Inc. (Nasdaq: CEMP) today announced the dosing of the first two patients enrolled in a Phase 2 clinical trial to evaluate the efficacy, safety and tolerability of solithromycin in the treatment of uncomplicated urogenital gonococcal infections.
5/10/2012 Cempra, Inc. Reports First Quarter 2012 Financial and Operating Results
CHAPEL HILL, N.C. – May 10, 2012 – Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the first quarter ended March 31, 2012. The company will host a conference call and webcast at 4:30 p.m. EDT, today.
5/3/2012 Cempra, Inc. to Report First Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on May 10, 2012
CHAPEL HILL, N.C., May 3, 2012 - Cempra, Inc. (Nasdaq: CEMP) today announced that it will report first quarter 2012 financial results and provide a business update after the close of U.S. financial markets on May 10, 2012. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra will host a conference call and webcast at 4:30 p.m. EDT, May 10, 2012.
4/13/2012 Cempra, Inc. to Present at the BioCentury Future Leaders Conference
Chapel Hill, N.C., Apr. 13, 2012 – Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at the Future Leaders in the Biotechnology Industry conference at 1:30 p.m. EDT, Apr. 20, 2012, at the Millennium Broadway Hotel in New York.
3/31/2012 Cempra Inc.'s Solithromycin (CEM-101) Demonstrates In Vitro Activity Against Antibiotic-Resistant Neisseria Gonorrhoeae Isolates
CHAPEL HILL, N.C., March 31, 2012 - Cempra Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) demonstrating that CEM-101 (solithromycin) is active against antibiotic-resistant strains of N. gonorrhoeae.
3/31/2012 Cempra Inc. Presents Full Data Set of Phase 2 Clinical Trial of CEM-101 (Solithromycin) in Community-Acquired Bacterial Pneumonia Patients at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
CHAPEL HILL, N.C., March 31, 2012 - Cempra Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)...
3/30/2012 Cempra, Inc. Reports Full Year 2011 Financial Results
CHAPEL HILL, N.C., March 30, 2012 - Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the full year ended December 31, 2011.
3/29/2012 Cempra, Inc. to Present at the Needham 11th Annual Health Care Conference
Chapel Hill, N.C., Mar. 29, 2012 – Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at the Needham11th Annual Health Care Conference at 10:40 a.m. EDT, Apr.4, 2012, at the Palace Hotel in New York.  
2/29/2012 Cempra, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference
- Cempra, Inc. (NASDAQ: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at the Cowen and Company 32nd Annual Health Care Conference at 11:20 a.m. EST, March 6, 2012, at The Boston Marriott Copley Place in Boston....
2/27/2012 Cempra, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares
- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the underwriters of its recent initial public offering have exercised in....
2/8/2012 Cempra, Inc. Announces Closing of Initial Public Offering of Common Stock
- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it successfully closed its previously announced initial public offering of....
2/3/2012 Cempra, Inc. Announces Pricing of Its Initial Public Offering of Common Stock
- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the pricing of its initial public offering of 8,400,000 shares of its common....
11/3/2011 TakstaTM (fusidic acid) Demonstrates Activity against MRSA Isolated from Cystic Fibrosis Patients
- Cempra Pharmaceuticals will be presenting data demonstrating Taksta's activity against Methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from cystic fibrosis (CF) patients and demonstrating solithromycin's anti-inflammatory activity in a human lung epithelial....
10/20/2011 Additional Data on the Mechanistic Characterization of Adverse Events of Voriconazole and Telithromycin to be Presented at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA)
- Additional data will be presented on the mechanistic characterization of adverse events reported with the azole antifungal, voriconazole, and the ketolide antibiotic, telithromycin, at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA). The....
10/12/2011 Cempra Holdings, LLC Files Registration Statement for Proposed Initial Public Offering
- Cempra Holdings, LLC, the parent holding company of Cempra Pharmaceuticals, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to its proposed initial public offering.....
9/16/2011 Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
- Cempra Pharmaceuticals today announced abstracts to be presented on its fourth generation macrolide and novel fluoroketolide antibiotic, solithromycin (CEM-101), at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17 to 20, 2011....
9/15/2011 Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP)
- Cempra Pharmaceuticals today announced results from its Phase II clinical trial investigating the efficacy, safety and tolerability of oral administration of our fourth generation macrolide, solithromycin (CEM-101), a fluoroketolide antibiotic, in comparison with oral....
5/31/2011 Cempra Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Jefferies 2011 Global Healthcare Conference at 1:30 p.m. EDT, June 6, 2011, at the Grand Hyatt in New York City. Dr. Fernandes will provide....
5/18/2011 Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris
- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at two upcoming investor conferences in Paris. Dr. Fernandes will present at 18th Annual Euro-Biotech Forum at 9:45 a.m. CET, May 24, at the...
5/7/2011 Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
- Cempra Pharmaceuticals, a developer of differentiated antibiotics, today announced an oral presentation showing that intravenous (IV) solithromycin demonstrates excellent tolerability and a favorable pharmacokinetic (PK) profile at IV doses up to 800 mg. Oral administration...
5/2/2011 Fusidic Acid (TAKSTA™, CEM-102) is Active, In Vitro, Against Methicillin-Resistant Staphylococcus Aureus (MRSA) Strains Isolated from Cystic Fibrosis Patients
- Researchers from the Hershey Medical Center today announced the publication of research demonstrating that the antibiotic, fusidic acid, is active against MRSA strains isolated from cystic fibrosis (CF) patients. In addition, fusidic acid did not antagonize the activity of...
5/2/2011 Cempra Pharmaceuticals to Present Data on Solithromycin (CEM-101) and TAKSTATM (CEM-102) at the 21st European Congress of Clinical Microbiology and Infectious Disease (ECCMID)/27th International Congress of Chemotherapy (ICC)
- Cempra Pharmaceuticals, a developer of differentiated antibiotics, today announced its schedule of presentations at the 21st European Congress of Clinical Microbiology and Infectious Disease (ECCMID)/27th International Congress of Chemotherapy (ICC) in Milan, Italy, May 7-10, 2011...
4/28/2011 Fusidic Acid (TAKSTATM, CEM-102) is Active, In Vitro, Against Methicillin-Resistant Staphylococcus Aureus (MRSA) Strains Isolated from Cystic Fibrosis Patients
- Researchers from the Hershey Medical Center today announced the publication of research demonstrating that the antibiotic, fusidic acid, is active against MRSA strains isolated from cystic fibrosis (CF) patients. In addition, fusidic acid did not antagonize the activity of two...
4/7/2011 Cempra Pharmaceuticals To Present At Two Upcoming Cambridge Healthtech Institute (CHI) Conferences
- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at two upcoming CHI conferences. Dr. Fernandes will present at the Second Annual Anti-Inflammatories: Small Molecule Approaches Conference at 5 p.m. PDT, April 12, at the Hilton San Diego Resort in San Diego. Her presentation is entitled...
3/30/2011 Cempra Pharmaceuticals To Present At Two Upcoming Investor Conferences
- Cempra Pharmaceuticals Inc. today announced presentations at two upcoming investor conferences. Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at the Needham & Company 10th Annual Healthcare Conference at 10 a.m. EDT, April 6, at The New York Palace...
3/3/2011 Cempra Expands Clinical Management Team To Advance Leading Antibacterial Clinical Programs Solithromycin and Takstatm
- Cempra Pharmaceuticals today announced the appointment of David Oldach, M.D. as vice president, clinical research as well as announcing an expansion of its clinical development team to manage the company's leading clinical programs, solithromycin and TAKSTA through advanced clinical...
3/2/2011 Cempra Pharmaceuticals To Present at the Cowen And Company 31st Annual Health Care Conference
- Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for...
1/12/2011 Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (Cem-101) at the 5th Annual Phemce Stakeholders Workshop and Barda Industry Day
- Cempra Pharmaceuticals presented the broad spectrum and potent activity profile of solithromycin (CEM-101), the first fluoroketolide antibiotic, at the 5th Annual PHEMCE stakeholders workshop and Biomedical Advanced Research and Development Authority (BARDA) industry day on January 10 to 12...
1/5/2011 Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
- Cempra Pharmaceuticals announced that Carl Foster has been named Executive Vice President of Business Development. Mr. Foster will be focusing on business development activities related to the company's two lead antibiotic programs, the next-generation fluoroketolide solithromycin (CEM-101)...
12/1/2010 Molecular Mechanisms That Could Explain Unique Adverse Events Observed in Patients Treated With the Antibiotic Telithromycin (Ketektm) is Reported in Antimicrobial Agents and Chemotherapy
- Cempra Pharmaceuticals and HiQScreen today announced the publication of research revealing the molecular mechanisms that could explain certain unique adverse events associated with the ketolide, telithromycin (KetekTM), which led to its restricted use. The study also showed...
11/15/2010 Cempra Pharmaceuticals To Present At The Lazard 7th Annual Healthcare Conference
Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Lazard 7th Annual Healthcare Conference at 9:00 a.m. EST, November 17, 2010, at the St. Regis New York in New York City. Dr. Fernandes will...
11/3/2010 Cempra Pharmaceuticals' Solithromycin (Cem-101) Demonstrates Potent In Vitro And In Vivo Activity Against Malaria
Cempra Pharmaceuticals today announced abstracts to be presented on its novel fluoroketolide antibiotic, solithromycin (CEM-101), at the American Society of Tropical Medicine and Hygiene 59th Annual Meeting, November 3 to 7 in Atlanta. The abstracts will present new information on solithromycin's...
10/15/2010 Cempra Pharmaceuticals Presents New Data on its Multi-Drug Resistant Anti-Infective Portfolio, Solithromycin (Cem-101) and Takstatm (Cem-102), at the 48th Annual Meeting of the Infectious Diseases Society of America
Cempra Pharmaceuticals today announced poster presentations on its novel fluoroketolide antibiotic, solithromycin (CEM-101), and the Company's proprietary front-loading oral dosing regimen of sodium fusidate, TAKSTA (CEM-102) at the 48th Annual Meeting...
10/12/2010 Cempra Pharmaceuticals Names Richard Kent, M.D., to its Board of Directors
Cempra Pharmaceuticals announced that Richard Kent, M.D., a partner at Intersouth Partners, has been appointed to Cempra's board of directors. Dr. Kent will replace Garheng Kong, M.D., Ph.D., M.B.A., as Intersouth's representative on the board. Dr. Kong, who has...
9/14/2010 Cempra Pharmaceuticals to Present at the Stifel Nicolaus Healthcare Conference 2010
Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Stifel Nicolaus Healthcare Conference 2010 at 10:20 a.m. EDT, September 16, 2010, at the Four Seasons Hotel in Boston. Dr. Fernandes...
9/9/2010 Cempra Pharmaceuticals Presents New Data On TakstaTM (Cem-102, Sodium Fusidate) At The 50th Interscience Conference On Antimicrobial Agents And Chemotherapy (Icaac)
Cempra Pharmaceuticals today announced abstracts to be presented on its oral anti-MRSA antibiotic, TAKSTA (sodium fusidate, formerly CEM-102), at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 12 to 15, 2010, in Boston...
9/9/2010 Cempra Pharmaceuticals Presents New Data On Its Next Generation Fluoroketolide, Solithromycin (Cem-101) At The 50th Interscience Conference On Antimicrobial Agents And Chemotherapy (Icaac)
Cempra Pharmaceuticals today announced abstracts to be presented on its novel fluoroketolide antibiotic, solithromycin (CEM-101), at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 12 to 15, 2010, in Boston...
9/8/2010 Cempra Pharmaceuticals Will Present New Data On Solithromycin (Cem-101) And Takstatm (Cem-102) At The 50th Interscience Conference On Antimicrobial Agents And Chemotherapy (Icaac)
Cempra Pharmaceuticals today announced its schedule of 16 poster presentations at the 50TH Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, Mass., on September 12-15, 2010...
9/8/2010 Cempra Pharmaceuticals Initiates Both a Phase 2 Study With an Oral Formulation and a Phase 1 Study of the Intravenous Formulation of Solithromycin (CEM-101), a Novel Fluoroketolide
Cempra Pharmaceuticals announced that it is moving forward in its dual approach to the development of solithromycin (CEM-101), a fluoroketolide which is first of a new generation of macrolide-ketolide antibiotics for treatment of community-acquired...
5/18/2010 Cempra Pharmaceutical's Cem-101 Demonstrates Potent Anti-Inflammatory Activity, Compared To Other Macrolide Antibiotics, In An Inflammation Cell Model At The American Thoracic Society 2010 International Conference
Cempra Pharmaceuticals today announced the results from two poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, at the American Thoracic Society 2010 International Conference, May 14 to 19, 2010, in New Orleans...
5/6/2010 Cempra Pharmaceuticals Names Mark W. Hahn as Executive Vice President and Chief Financial Officer
Cempra Pharmaceuticals Inc. today announced the appointment of Mark W. Hahn as executive vice president and chief financial officer...
5/4/2010 Cempra Announces Positive Results From Its Phase 2 Clinical Trial Of Takstatm (Sodium Fusidate) In Patients With Acute Bacterial Skin And Skin Structure Infections (Absssi)
Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA™ (CEM-102, sodium fusidate), the company’s oral, anti-methicillinresistant Staphylococcus aureus (MRSA) antibiotic. The study demonstrated efficacy...
4/10/2010 Cempra pharmaceuticals presents new data on its multi-drug resistant anti-infective portfolio, cem-101 and takstatm (cem-102), at the 20th european congress of clinical microbiology and infectious disease
Cempra Pharmaceuticals today announced poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, and CEM-102 (TAKSTA), the company's proprietary front-loading oral dosing regimen of sodium fusidate, at the 20th European Congress of Clinical Microbiology...
4/8/2010 Cempra pharmaceuticals will present new data on cem-101 and takstatm (cem-102) at the 20th european congress of clinical microbiology and infectious disease
Cempra Pharmaceuticals today announced its schedule of poster presentations at the 20th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna, Austria, on April 10-13, 2010....
4/6/2010 Cempra announces expansion of clinical management team to advance leading antibacterial clinical programs takstatm and cem-101
Cempra Pharmaceuticals today announced the expansion of its clinical development team to manage the company's leading clinical programs, CEM-101 and TAKSTA (formerly CEM-102) through advanced clinical development. The four appointments, including Susan R. Moriarty, M.D. and Jennifer ....
3/10/2010 Cempra announces The Completion of Phase 1 Studies for cem-101, a next-generation macrolide
Cempra Pharmaceuticals today announced the successful completion of Phase 1 clinical trials of its oral formulation of CEM-101, which showed good tolerability in those studies. The company also announced plans to submit an IND to the FDA to begin a Phase 1 study....
3/4/2010 Cempra Pharmaceuticals To Present At The Cowen And Company 30th Annual Health Care Conference
Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Cowen and Company 30th Annual Health Care Conference at 3 p.m. EST, March 8, 2010, at The Boston Marriott Copley Place in Boston...
1/19/2010 Cempra Completes Enrollment Of Phase 2 Portion Of Phase 2/3 Clinical Trial Of Takstatm (Cem-102 Or Sodium Fusidate) For Treatment Of Acute Bacterial Skin And Structure Infections
Cempra Pharmaceuticals today announced completion of enrollment of the Phase 2 portion of its Phase 2/3 clinical trial of TAKSTA...
1/8/2010 Cempra Pharmaceuticals Names Donald C. Olsen Executive Vice President Of Business Development
Cempra Pharmaceuticals Inc. today announced the appointment of Donald C. Olsen as executive vice president of business development. Mr. Olsen will oversee the...
11/25/2009 Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Piper Jaffray 21st Annual Health Care Conference...
11/13/2009 Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will...
10/29/2009 Data Presented on Cempra Pharmaceutical's CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
Cempra Pharmaceuticals today announced a presentation on its novel fluoroketolide antibiotic, CEM-101, at the Infectious Diseases Society of America...
10/29/2009 Presentations of Cempra Pharmaceutical's CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
Cempra Pharmaceuticals today announced data presentations of its lead antibiotic candidate, CEM-102 (fusidic acid)...
10/22/2009 Cempra Pharmaceuticals Will Present New Data on CEM-101 and CEM-102 at the Infectious Disease Society Of America, 47th Annual Meeting
Cempra Pharmaceuticals today announced its schedule of oral and poster presentations at the Infectious Disease Society of America...
09/09/2009 Cempra Pharmaceuticals Initiates Phase 2/3 Clinical Study for an Oral Antibiotic to Treat Acute Bacterial Skin Structure Infections
Cempra Pharmaceuticals today announced that enrollment is underway in an adaptive design Phase 2/3 clinical study with CEM-102 for patients suffering...
08/12/2009 Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
Cempra Pharmaceuticals today announced the appointment of John H. Johnson, Chief Executive Officer of ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to the company’s Board of Directors...
05/14/2009 Cempra Pharmaceuticals Closes $46M Series C Financing
Funds will advance clinical development of two lead antibiotic compounds and the company's pre-clinical pipeline...
04/28/2009 Cempra Pharmaceuticals Inc. announces lead macrolide is active in vitro against clinically significant antibiotic-resistant pathogenic organisms
Cempra Pharmaceuticals today announced the publication of new research in the May issue of Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology, demonstrating that its lead compound, CEM-101 ...
09/30/2008 Cempra Pharmaceuticals and Biovista Enter Agreement For Macrolide Clinical Trial Design Support Studies
Cempra Pharmaceuticals, Inc., and Biovista, Inc., announced today that they have entered into a research agreement to systematically identify and profile adverse event associations for members of the macrolide drug class ...
10/03/2006 Aisling Capital Joins I. Wistar Morris III and Intersouth Partners as a Lead Investor in Cempra Pharmaceuticals
Anti-infective biotechnology company Cempra Pharmaceuticals announced today that it has added Aisling Capital as an investor ...
08/16/2006 Cempra Pharmaceuticals Raises $14 Million Round of Financing
Cempra Pharmaceuticals, a biotechnology company developing anti-infective medicines ...
04/04/2006 Cempra Pharmaceuticals Receives Exclusive Rights from Optimer Pharmaceuticals for Its Macrolide Antibacterial Program
Cempra Pharmaceuticals, Inc. announced that Optimer Pharmaceuticals has granted to Cempra exclusive worldwide rights (except ASEAN countries ...